A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

Paul A. Foster, Surinder K. Chander, Simon P. Newman, L. W. Lawrence Woo, Oliver B. Sutcliffe, Christian Bubert, Dujin J. Zhou, Shiuan A. Chen, Barry V. L. Potter, Michael J. Reed, Atul Purohit

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: The production of E2 is paramount for the growth of estrogen receptor - positive breast cancer. Various strategies have been used, including the use of enzyme inhibitors against either aromatase (AROM) or steroid sulfatase (STS), in an attempt to ablate E2 levels. Both these enzymes play a critical role in the formation of estrogenic steroids and their inhibitors are now showing success in the clinic. Experimental Design: We show here, in a xenograft nude mouse model, that the inhibition of both enzymes using STX681, a dual AROM and STS inhibitor (DASI), is a potential new therapeutic strategy against HDBC. MCF-7 cells stably expressing either AROM cDNA (MCF-7(AROM)) or STS cDNA (MCF-7(STS)) were generated. Ovariectornized MF-1 female nude mice receiving s.c. injections of either androstenedione (A(4)) or E2 sulfate and bearing either MCF-7(AROM) or MCF-7(STS) tumors were orally treated with STX64, letrozole, or STX681. Treatment was administered for 28 days. Mice were weighed and tumor measurements were taken weekly. Results: STX64, a potent STS inhibitor, completely blocked MCF-7(STS) tumor growth but failed to attenuate MCF-7(AROM) tumor growth. In contrast, letrozole inhibited MCF-7(AROM) tumors but had no effect on MCF-7(STS) tumors. STX681 completely inhibited the growth of both tumors. AROM and STS activity was also completely inhibited by STX681, which was accompanied by a significant reduction in plasma E2 levels. Conclusions: This study indicates that targeting both the AROM and the STS enzyme with a DASI inhibits HDBC growth and is therefore a potentially novel treatment for this malignancy.
Original languageEnglish
Pages (from-to)6469-6477
JournalClinical Cancer Research
Volume14
Issue number20
DOIs
Publication statusPublished - 15 Oct 2008

Keywords

  • steroid sulfatase
  • estrone
  • sulfatase
  • in-vivo activity
  • nude-mouse model
  • tamoxifen
  • endocrine therapy
  • mcf-7 cells
  • postmenopausal women
  • letrozole
  • receptor content

Fingerprint Dive into the research topics of 'A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor'. Together they form a unique fingerprint.

  • Cite this

    Foster, P. A., Chander, S. K., Newman, S. P., Woo, L. W. L., Sutcliffe, O. B., Bubert, C., Zhou, D. J., Chen, S. A., Potter, B. V. L., Reed, M. J., & Purohit, A. (2008). A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Clinical Cancer Research, 14(20), 6469-6477. https://doi.org/10.1158/1078-0432.ccr-08-1027